Compounds > cefathiamidine
Page last updated: 2024-11-12

cefathiamidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cefathiamidine: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID15942748
CHEMBL ID4303356
CHEBI ID134698
MeSH IDM0070848

Synonyms (32)

Synonym
cefathiamidine
7-(alpha-((n,n'-diisopropylamidino)thio)acetylamino)cephalosporanic acid
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(2-((n,n'-diisopropylamidino)thio)acetamido)-3-(hydroxymethyl)-8-oxo-, acetate
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((acetyloxy)methyl)-7-((((((1-methylethyl)amino)((1-methylethyl)imino)methyl)thio)acetyl)amino)-8-oxo-, (6r-trans)-
LS-150050 ,
CHEBI:134698
33075-00-2
unii-8m7cas5t8l
8m7cas5t8l ,
3-chloromethylacetophenone
AKOS025311505
(6r,7r)-7-(2-((n,n'-diisopropylamidino)thio)acetamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid acetate (ester)
xianlisu
(7r)-7-(2-((n,n'-diisopropylamidino)thio)acetamido)cephalosporanic acid
cefathiamidine [who-dd]
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((acetyloxy)methyl)-7-((2-((((1-methylethyl)amino)((1-methylethyl)imino)methyl)thio)acetyl)amino)-8-oxo-, (6r,7r)-
(6r,7r)-3-(acetoxymethyl)-7-(2-(((z)-n,n'-diisopropylcarbamimidoyl)thio)acetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
cefathiamidine impurity 3
CS-0028153
HY-107329
AS-16044
(6r,7r)-3-(acetoxymethyl)-7-(2-(((e)-n,n'-diisopropylcarbamimidoyl)thio)acetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
BCP11974
CCG-269465
CHEMBL4303356
Q27270750
D81831
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(2-((n,n'-diisopropyla
A918837
(6r,7r)-3-(acetyloxymethyl)-7-[[2-[n,n'-di(propan-2-yl)carbamimidoyl]sulfanylacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
S4880
5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,3-[(acetyloxy)methyl]-7-[[[[[(1-methylethyl)amino][(1-methylethyl)imino]methyl]thio]acetyl]amino]-8-oxo-, (6r,7r)-

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" As pharmacokinetic data are limited in the pediatric population, we aimed to evaluate the population pharmacokinetics of cefathiamidine in children and to define the appropriate dose in order to optimize cefathiamidine treatment."( Population pharmacokinetics and dosing optimization of cefathiamidine in children with hematologic infection.
Chen, XK; Dong, L; Jacqz-Aigrain, E; Shi, ZR; Wang, L; Wen, L; Zhai, XY; Zhao, W; Zhi, LJ, 2018)		0.94
" Population pharmacokinetic analysis was conducted using NONMEM software."( Population pharmacokinetics and dosing optimization of cefathiamidine in children with hematologic infection.
Chen, XK; Dong, L; Jacqz-Aigrain, E; Shi, ZR; Wang, L; Wen, L; Zhai, XY; Zhao, W; Zhi, LJ, 2018)		0.73
" Sparse pharmacokinetic samples (n=120) were available for analysis."( Population pharmacokinetics and dosing optimization of cefathiamidine in children with hematologic infection.
Chen, XK; Dong, L; Jacqz-Aigrain, E; Shi, ZR; Wang, L; Wen, L; Zhai, XY; Zhao, W; Zhi, LJ, 2018)		0.73

Dosage Studied

ExcerptRelevanceReference
" Monte Carlo simulation demonstrated that the currently used dosing regimen of 100 mg/kg/day q12h was associated with a high risk of underdosing in pediatric patients."( Population pharmacokinetics and dosing optimization of cefathiamidine in children with hematologic infection.
Chen, XK; Dong, L; Jacqz-Aigrain, E; Shi, ZR; Wang, L; Wen, L; Zhai, XY; Zhao, W; Zhi, LJ, 2018)		0.73
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
cephalosporinA class of beta-lactam antibiotics differing from the penicillins in having a 6-membered, rather than a 5-membered, side ring. Although cephalosporins are among the most commonly used antibiotics in the treatment of routine infections, and their use is increasing over time, they can cause a range of hypersensitivity reactions, from mild, delayed-onset cutaneous reactions to life-threatening anaphylaxis in patients with immunoglobulin E (IgE)-mediated allergy.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID1671773Antibacterial activity against Staphylococcus aureus assessed as bacterial growth inhibition in presence of 2-(4-(3-(2-aminothiazol-4-yl)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinolin-7-yl)piperazin-1-yl)acetonitrile by CLSI protocol based two fold serial di2019European journal of medicinal chemistry, Apr-01, Volume: 167Design and synthesis of aminothiazolyl norfloxacin analogues as potential antimicrobial agents and their biological evaluation.
AID1671772Antibacterial activity against Klebsiella pneumoniae assessed as bacterial growth inhibition in presence of 2-(4-(3-(2-aminothiazol-4-yl)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinolin-7-yl)piperazin-1-yl)acetonitrile by CLSI protocol based two fold serial di2019European journal of medicinal chemistry, Apr-01, Volume: 167Design and synthesis of aminothiazolyl norfloxacin analogues as potential antimicrobial agents and their biological evaluation.
AID1671808Antibacterial activity against Staphylococcus aureus assessed as inhibition of bacterial growth after 24 hrs by CLSI protocol based two fold serial dilution method2019European journal of medicinal chemistry, Apr-01, Volume: 167Design and synthesis of aminothiazolyl norfloxacin analogues as potential antimicrobial agents and their biological evaluation.
AID1671771Antibacterial activity against Escherichia coli assessed as bacterial growth inhibition in presence of 2-(4-(3-(2-aminothiazol-4-yl)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinolin-7-yl)piperazin-1-yl)acetonitrile by CLSI protocol based two fold serial dilutio2019European journal of medicinal chemistry, Apr-01, Volume: 167Design and synthesis of aminothiazolyl norfloxacin analogues as potential antimicrobial agents and their biological evaluation.
AID1671810Antibacterial activity against methicillin-resistant Staphylococcus aureus N315 assessed as inhibition of bacterial growth after 24 hrs by CLSI protocol based two fold serial dilution method2019European journal of medicinal chemistry, Apr-01, Volume: 167Design and synthesis of aminothiazolyl norfloxacin analogues as potential antimicrobial agents and their biological evaluation.
AID1671766Potentiation of 2-(4-(3-(2-aminothiazol-4-yl)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinolin-7-yl)piperazin-1-yl)acetonitrile-induced antibacterial activity against Klebsiella pneumoniae assessed as fold reduction in 2-(4-(3-(2-aminothiazol-4-yl)-1-ethyl-6-fl2019European journal of medicinal chemistry, Apr-01, Volume: 167Design and synthesis of aminothiazolyl norfloxacin analogues as potential antimicrobial agents and their biological evaluation.
AID1671804Antibacterial activity against Escherichia coli assessed as inhibition of bacterial growth after 24 hrs by CLSI protocol based two fold serial dilution method2019European journal of medicinal chemistry, Apr-01, Volume: 167Design and synthesis of aminothiazolyl norfloxacin analogues as potential antimicrobial agents and their biological evaluation.
AID1671774Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as bacterial growth inhibition in presence of 2-(4-(3-(2-aminothiazol-4-yl)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinolin-7-yl)piperazin-1-yl)acetonitrile by CLSI protocol ba2019European journal of medicinal chemistry, Apr-01, Volume: 167Design and synthesis of aminothiazolyl norfloxacin analogues as potential antimicrobial agents and their biological evaluation.
AID1671805Antibacterial activity against Klebsiella pneumoniae assessed as inhibition of bacterial growth after 24 hrs by CLSI protocol based two fold serial dilution method2019European journal of medicinal chemistry, Apr-01, Volume: 167Design and synthesis of aminothiazolyl norfloxacin analogues as potential antimicrobial agents and their biological evaluation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (14.29)18.7374
1990's0 (0.00)18.2507
2000's2 (28.57)29.6817
2010's4 (57.14)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.92 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (28.57%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (14.29%)4.05%
Observational0 (0.00%)0.25%
Other4 (57.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
urea
pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.		2.110isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
fluconazole
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.		2.2110conazole antifungal drug;
difluorobenzene;
tertiary alcohol;
triazole antifungal drug		environmental contaminant;
P450 inhibitor;
xenobiotic
gentamicin
Gentamicins: A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS.		6.9610
norfloxacin
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.. norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.		2.2110fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug;
DNA synthesis inhibitor;
environmental contaminant;
xenobiotic
ampicillin
Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.		6.9610beta-lactam antibiotic;
penicillin allergen;
penicillin		antibacterial drug
cephalosporin c
cephalosporin C: RN given refers to parent cpd; structure in Merck, 9th ed, #1937. cephalosporin C : A cephalosporin antibiotic carrying a 3-acetoxymethyl substituent and a 6-oxo-N(6)-L-lysino group at position 7.		5.2362cephalosporinfungal metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Neisseria gonorrhoeae Infection
[description not available]		02.1510
Gonorrhea
Acute infectious disease characterized by primary invasion of the urogenital tract. The etiologic agent, NEISSERIA GONORRHOEAE, was isolated by Neisser in 1879.		02.1510
Haemophilus Infections
Infections with bacteria of the genus HAEMOPHILUS.		03.5611
Bacterial Disease
[description not available]		03.411
Emesis
[description not available]		03.411
Bacterial Infections
Infections by bacteria, general or unspecified.		03.411
Diarrhea
An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.		03.411
Nausea
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.		03.411
Vomiting
The forcible expulsion of the contents of the STOMACH through the MOUTH.		03.411